Unison Advisors LLC Purchases 564 Shares of CVS Health Corporation $CVS

Unison Advisors LLC boosted its position in shares of CVS Health Corporation (NYSE:CVS) by 1.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 54,864 shares of the pharmacy operator’s stock after purchasing an additional 564 shares during the period. Unison Advisors LLC’s holdings in CVS Health were worth $3,785,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. boosted its holdings in shares of CVS Health by 87.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 9,927,650 shares of the pharmacy operator’s stock worth $672,598,000 after acquiring an additional 4,632,530 shares in the last quarter. Dodge & Cox boosted its stake in CVS Health by 4.8% in the first quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock worth $4,976,856,000 after purchasing an additional 3,353,223 shares in the last quarter. Nuveen LLC bought a new stake in shares of CVS Health during the first quarter worth $204,421,000. Invesco Ltd. increased its stake in shares of CVS Health by 13.2% in the first quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator’s stock valued at $1,383,039,000 after buying an additional 2,375,764 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. raised its holdings in shares of CVS Health by 815.2% in the second quarter. Robeco Institutional Asset Management B.V. now owns 2,663,111 shares of the pharmacy operator’s stock valued at $183,701,000 after buying an additional 2,372,121 shares during the last quarter. 80.66% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on CVS shares. Sanford C. Bernstein increased their price objective on shares of CVS Health from $72.00 to $77.00 and gave the stock a “market perform” rating in a report on Friday, September 5th. The Goldman Sachs Group initiated coverage on shares of CVS Health in a report on Tuesday, October 14th. They issued a “buy” rating and a $91.00 price target for the company. Cowen restated a “buy” rating on shares of CVS Health in a research report on Monday, August 4th. Wolfe Research increased their price objective on CVS Health from $80.00 to $85.00 and gave the company an “outperform” rating in a research report on Monday, September 22nd. Finally, Morgan Stanley boosted their target price on CVS Health from $82.00 to $89.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 14th. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $82.57.

Insiders Place Their Bets

In related news, Director Anne A. Finucane sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total transaction of $532,650.00. Following the completion of the transaction, the director owned 22,156 shares in the company, valued at approximately $1,573,519.12. The trade was a 25.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.22% of the stock is owned by insiders.

CVS Health Stock Performance

Shares of CVS Health stock opened at $82.64 on Monday. The firm has a fifty day moving average of $74.00 and a two-hundred day moving average of $68.12. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 0.80. The stock has a market capitalization of $104.81 billion, a price-to-earnings ratio of 23.08, a PEG ratio of 0.91 and a beta of 0.60. CVS Health Corporation has a 52 week low of $43.56 and a 52 week high of $82.88.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.35. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The business had revenue of $98.92 billion during the quarter, compared to analysts’ expectations of $94.87 billion. During the same period in the previous year, the firm earned $1.83 earnings per share. The firm’s quarterly revenue was up 8.4% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts predict that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Thursday, October 23rd will be given a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date is Thursday, October 23rd. CVS Health’s dividend payout ratio (DPR) is currently 74.30%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.